We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Efficacy of Cancer Immunotherapy: An Umbrella Review of Meta-Analyses of Randomized Controlled Trials.
- Authors
Kim, Jong Yeob; Lee, Keum Hwa; Eisenhut, Michael; van der Vliet, Hans J.; Kronbichler, Andreas; Jeong, Gwang Hun; Shin, Jae Il; Gamerith, Gabriele
- Abstract
We conducted a systematic review for evidence of the clinical efficacy of cancer immunotherapies. We searched PubMed from inception to 14 February 2018 for meta-analyses of randomized controlled trials (RCTs) of cancer immunotherapies. Re-analyses were performed to estimate the summary effect size under random-effects, the 95% confidence interval (CI), heterogeneity, and the 95% prediction interval, and we determined the strength of the evidence. We examined publication bias and excess significance bias. 63 articles corresponding to 247 meta-analyses were eligible. Nine meta-analyses were classified to have convincing evidence, and 75 were classified as suggestive evidence. The clinical benefit of immunotherapy was supported by convincing evidence in the following settings: anti-PD-1/PD-L1 monoclonal antibody (mAb) therapy for treating advanced melanoma and non-small cell lung cancer (NSCLC), the combination of rituximab and chemotherapy for treating chronic lymphocytic leukemia and B-cell non-Hodgkin's lymphoma, adoptive cell immunotherapy for NSCLC, and the combination of interferon α and chemotherapy for metastatic melanoma. A further meta-analysis of 16 RCTs showed that anti-PD-1/PD-L1 mAb therapy had a benefit in patients with solid tumors (overall survival; hazard ratio = 0.73, 95% CI: 0.68–0.79; p < 0.001), supported by convincing evidence. In the future, rigorous approaches are needed when interpreting meta-analyses to gain better insight into the true efficacy of cancer immunotherapy.
- Subjects
THERAPEUTIC use of interferons; THERAPEUTIC use of monoclonal antibodies; RITUXIMAB; ANTINEOPLASTIC agents; CANCER chemotherapy; CHRONIC lymphocytic leukemia; CONFIDENCE intervals; IMMUNOTHERAPY; LUNG cancer; LYMPHOMAS; MEDLINE; MELANOMA; METASTASIS; ONLINE information services; SURVIVAL; TUMORS; SYSTEMATIC reviews; TREATMENT effectiveness; DESCRIPTIVE statistics
- Publication
Cancers, 2019, Vol 11, Issue 11, p1801
- ISSN
2072-6694
- Publication type
Article
- DOI
10.3390/cancers11111801